Does magnetic stimulation of the brain improve the symptoms of obsessive-compulsive disorder?

Accelerated deep intermittent theta-burst stimulation of medial prefrontal/anterior cingulate cortex for medication-resistant obsessive-compulsive disorder: A multi-site randomised sham-controlled trial - NIL

Status

Active, not recruiting

Phases

Phase 2Phase 3

Study type

Interventional

Source

CTRI

Registry ID

CTRI/2025/08/092300

Enrollment

108

Registered

2025-08-04

Start date

Unknown

Completion date

Unknown

Last updated

2025-08-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Health Condition 1: F422- Mixed obsessional thoughts and acts

Interventions

Intervention1: Intermittent Theta Burst Stimulation (iTBS): Accelerated iTBS targeting medial prefrontal cortex and anterior cingulate cortex, administered using Brainsway Model 104 stimulator and H7

Eligibility

Inclusion criteria

Inclusion criteria: Primary diagnosis of obsessive-compulsive disorder as per DSM-5 criteria, confirmed using the Diagnostic Interview for Anxiety, Mood, and OCD and Related Neuropsychiatric Disorders (DIAMOND). Inadequate response to at least one adequate trial of serotonin reuptake inhibitor. On stable psychotropic medications for a minimum of 8 weeks. Not undergoing cognitive behavioural therapy at the time of recruitment. Yale-Brown Obsessive Compulsive Scale score of 16 or higher. Clinical Global Impressions Severity score of 4 or higher.

Exclusion criteria

Exclusion criteria: Presence of comorbid psychotic disorders, bipolar disorder, or active substance use disorder (except nicotine or caffeine dependence). Active suicidality. History suggesting intellectual disability. Contraindications to repetitive transcranial magnetic stimulation or magnetic resonance imaging. Pregnancy. Presence of unstable medical conditions or severe neurological disorders requiring immediate medical attention.

Design outcomes

Primary

Measure	Time frame
Change in Yale-Brown Obsessive Compulsive Scale (Y-BOCS) severity score from baselineTimepoint: 1 week after intervention	—

Secondary

Measure	Time frame
Change in resting-state functional connectivity in anterior cingulate and prefrontal regions, Change in ACC functional connectivity, MRS glutamate levels and amplitude of ERNTimepoint: 1 week after the end of treatment;HAM-A and HAM-D scoresTimepoint: 1 week after end of treatment;Change in YBOCS, HAM-A and HAM-D score at the end of phase 2 and Phase 3Timepoint: 6 weeks and 12-18 weeks after the end of treatment	—

Measure

Time frame

Change in resting-state functional connectivity in anterior cingulate and prefrontal regions, Change in ACC functional connectivity, MRS glutamate levels and amplitude of ERNTimepoint: 1 week after the end of treatment;HAM-A and HAM-D scoresTimepoint: 1 week after end of treatment;Change in YBOCS, HAM-A and HAM-D score at the end of phase 2 and Phase 3Timepoint: 6 weeks and 12-18 weeks after the end of treatment

—

Countries

India

Contacts

Public ContactShyam Sundar Arumugham

National Institute of Mental Health and Neuro Sciences

a.shyamsundar@gmail.com9008600112

Outcome results

None listed

Source: CTRI (via WHO ICTRP) · Data processed: Feb 4, 2026